Ondine Biomedical, Inc. (GB:OBI)
LSE:OBI
Want to see GB:OBI full AI Analyst Report?
OBI Stock Chart & Stats
8.75 p
-0.23 p(-2.61%)
At close: 4:00 PM EST
8.75 p
-0.23 p(-2.61%)
Day’s Range― - ―
52-Week Range7.50 p - 18.50 p
Previous CloseN/A
Volume7.12K
Average Volume (3M)160.07K
Market Cap
£75.16M
Enterprise Value109.78M
Total Cash (Recent Filing)£10.58M
Total Debt (Recent Filing)£413.50K
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Sep 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding518,366,940
10 Day Avg. Volume119,918
30 Day Avg. Volume160,072
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)21.53
Price to Sales (P/S)28.32
P/FCF Ratio-3.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)£12.20M
Bulls Say, Bears Say
Bulls Say
Revenue Growth / Commercial TractionConsistent double-digit revenue growth indicates improving commercial traction and product adoption in target healthcare settings. Over 2-6 months this suggests the company can scale addressable market presence, validate demand, and improve operating leverage if cost structure stabilizes.
Modest Financial LeverageLow debt levels provide balance-sheet flexibility and reduce near-term default risk, allowing management to prioritize R&D and go-to-market investment without immediate heavy interest burden. This structural conservatism supports runway extension versus high-leverage peers.
Specialized Antimicrobial Technology And Niche MarketA differentiated, healthcare-focused photodisinfection technology addresses structural demand for infection prevention. Durable clinical need, regulatory barriers to entry, and specialized product positioning can create a sustainable competitive niche and support longer-term adoption by hospitals.
Bears Say
Large And Worsening Cash BurnSustained and growing operating cash outflows materially increase financing risk and dependency on external capital. Unless revenue scales rapidly or spending tightens, the company faces dilution or constrained investment, limiting strategic optionality over the medium term.
Material Gross Margin CompressionA sharp decline in gross margin undermines unit economics and raises the revenue threshold for profitability. If margin pressure reflects structural cost increases or unfavorable pricing, it will impede sustainable margin expansion as revenue grows and weaken long-term free cash flow potential.
Deep Net Losses And Equity VolatilityExtremely large reported losses and historic equity swings imply ongoing dilution risk and dependence on capital markets. This constrains strategic choices, can dilute existing shareholders, and raises execution risk if fundraising conditions tighten over the next several months.
Ondine Biomedical, Inc. News
OBI FAQ
What was Ondine Biomedical, Inc.’s price range in the past 12 months?
Ondine Biomedical, Inc. lowest share price was 7.50 p and its highest was 18.50 p in the past 12 months.
What is Ondine Biomedical, Inc.’s market cap?
Ondine Biomedical, Inc.’s market cap is £75.16M.
When is Ondine Biomedical, Inc.’s upcoming earnings report date?
Ondine Biomedical, Inc.’s upcoming earnings report date is Sep 30, 2026 which is in 104 days.
How were Ondine Biomedical, Inc.’s earnings last quarter?
Ondine Biomedical, Inc. released its earnings results on Jun 04, 2026. The company reported -0.019 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.019 p.
Is Ondine Biomedical, Inc. overvalued?
According to Wall Street analysts Ondine Biomedical, Inc.’s price is currently Overvalued.
Does Ondine Biomedical, Inc. pay dividends?
Ondine Biomedical, Inc. does not currently pay dividends.
What is Ondine Biomedical, Inc.’s EPS estimate?
Ondine Biomedical, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ondine Biomedical, Inc. have?
Ondine Biomedical, Inc. has 518,366,940 shares outstanding.
What happened to Ondine Biomedical, Inc.’s price movement after its last earnings report?
Ondine Biomedical, Inc. reported an EPS of -0.019 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.448%.
Which hedge fund is a major shareholder of Ondine Biomedical, Inc.?
Currently, no hedge funds are holding shares in GB:OBI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ondine Biomedical, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
40.62%
12-Months-Change
Fundamentals
Return on Equity
-506.43%
Trailing 12-Months
Asset Growth
9.57%
Trailing 12-Months
Company Description
Ondine Biomedical, Inc.
Ondine Biomedical Inc., a life sciences firm, specializes in the research, development, and commercialization of advanced antimicrobial photodisinfection therapies, operating both within Canada and internationally. Its foundational technology is Photodisinfection, a state-of-the-art, light-based topical antimicrobial approach designed to neutralize detrimental pathogens. The company's flagship product, Steriwave, is a medical device leveraging photodisinfection to eradicate harmful nasal pathogens, thereby significantly mitigating healthcare-acquired infections. Furthermore, Ondine Biomedical's development pipeline includes a topical antiviral treatment for the upper respiratory tract aimed at reducing SARS-CoV-2 viral load and transmission; a solution for addressing chronic rhinosinusitis; OND1002, an agent for disinfecting endotracheal tubes to decrease the occurrence of ventilator-associated pneumonia; and OND1003, formulated for the decolonization of burns and wounds. Established in 1996, the company maintains its corporate headquarters in Vancouver, Canada.
Technical Analysis
Avacta Group plc
―
SkinBioTherapeutics
―
4basebio UK Societas
―
Poolbeg Pharma Ltd.
―
Oxford Nanopore Technologies PLC
―
Options Prices
Currently, No data available
---